Exosens Shares Jump 5.44% Mid-Day Following Strategic Agreement
Exosens shares significantly advanced at mid-session on Monday, December 8, 2025, marking a rise of 5.44% to 47.45 euros, up from 45 euros the previous day. This increase, coupled with a low trading activity of 0.05% of the capital, reflects a renewed interest in the French specialist of amplification and detection technologies, in a context where the overall Parisian market is slightly declining.
Strategic Extension with Theon International Boosts Confidence
The upward movement of Exosens follows the announcement on December 3, of the extension of its long-term commercial agreement with Theon International, its main client, until 2030 for the supply of light intensifier tubes. This three-year extension reinforces the group's visibility on its future deliveries and secures its production capacities in a market where global supply remains structurally lower than demand. Theon plans to purchase over 400,000 tubes in the next five years, thus strengthening Exosens' positioning with European armed forces and in emerging markets. With a mid-session gain of 5.44%, the share price stands at 47.45 euros, representing a weekly increase of 13.11% and a quarterly rise of 29.47%. Over one year, the performance reaches 159.3%, significantly outperforming the CAC 40, which is up 9.09% over the same period. This positive momentum is explained by the supportive environment of the defense sector and the robustness of the group's order book, benefiting from a geopolitical context favorable to the demand for night vision equipment.
Technical Analysis Indicates Cautious Optimism
Technically, the stock price is near the resistance level at 49.60 euros, having approached this level during the session with a high at 47.45 euros. The 50-day moving average is at 45.40 euros, slightly surpassed by the current price, indicating a short-term bullish momentum. However, proximity to the upper Bollinger band, set at 48.24 euros, suggests caution regarding the immediate potential for further price increases. The Relative Strength Index (RSI), at 46, indicates a neutral position of the stock, with no overbought or oversold signals, allowing for a possible continuation of the movement. With a support level identified at 41 euros, the stock has a considerable safety margin in case of a decline. The one-month volatility, at 11.84, and the Average True Range (ATR) of 1.12 reflect moderate fluctuations, characteristic of a stock consolidating its recent gains.
Limited Trading Volume Highlights Targeted Buying
The absence of significant volumes during this session—with only 0.05% of the capital traded—indicates a movement driven more by targeted buying than by a massive flow of orders. The On-Balance Volume (OBV) index of 123,045 and the slightly negative Chaikin Money Flow (CMF) at -0.05 confirm moderate accumulation, without notable selling pressure. The stock benefits from a very low beta of 0.04, reflecting an almost total decorrelation from the CAC 40, which is down 0.15% at 8,102.3 points today. This session illustrates Exosens' ability to capture investors' attention despite a globally lackluster market, supported by solid commercial fundamentals and privileged exposure to a strategically expanding sector. The trajectory of the stock in the upcoming sessions will be one to watch, particularly its evolution relative to the near resistance of 50 euros.
